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            Introduction : Breast cancer is the most common cancer among Malaysian women. 
There are many prognostic factors contributing to the disease and the outcome of the patients. 
Triple negative breast cancers are defined by a lack of expression of oestrogen, progesterone, and 
c erbB-2 receptors. They tend to have a higher grade with a poorer outcome compared to non-
triple negative breast cancers. 
 
Objectives :  The study was carried out aiming to observe the association of triple 
negative (oestrogen receptor (ER), progesterone receptor (PR) and c erbB-2) breast cancer 
patients to the pathological (histological subtype, tumour grade, tumour size and lymph node 
involvement) and non pathological parameters (patient’s age and ethnicity).  
 
 
              
             Methodology :  Retrospective review of histopathology reports in Hospital Universiti 
Sains Malaysia from 1st January, 2002 to 31st December, 2004. Twenty three cases of triple 
negative breast cancer among 115 cases of breast cancer diagnosed in three years (2002 to 2004) 
were reviewed. They represented 20.0% of total breast cancer patients. 
 
             Results :  There were significant association between triple negative breast cancer with 
tumour size, lymph node involvement and lymphovascular invasion. However, age, race, 
histological subtype and histological grade did not show significant association.  
 
              Conclusion :  From these findings, we conclude that tumour size is the strongest factor 
associated with the triple negative breast cancer. Besides that, lymph node involvement is also 
associated with triple negative breast cancer. However, lymph vascular invasion is not associated 
with triple negative vascular breast cancer. 
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ABSTRACT 
 
 
Breast cancer is the most common cancer among Malaysian women. There are 
many prognostic factors contributing to the disease and the outcome of the patients. 
Triple negative breast cancers are defined by a lack of expression of oestrogen, 
progesterone, and c erbB-2 receptors. They tend to have a higher grade with a poorer 
outcome compared to non-triple negative breast cancers. Hence, a retrospective study 
was carried out aiming to observe the association of triple negative (oestrogen receptor 
(ER), progesterone receptor (PR) and c erbB-2) breast cancer patients to the pathological 
(histological subtype, tumour grade, tumour size and lymph node involvement) and non 
pathological parameters (patient’s age and ethnicity).  
 
Twenty three cases of triple negative breast cancer among 115 cases of breast 
cancer diagnosed in three years (2002 to 2004) were reviewed. They represented 20.0% 
of total breast cancer patients. 
 
There were significant association between triple negative breast cancer with 
tumour size, lymph node involvement and lymphovascular invasion. However, age, race, 
histological subtype and histological grade did not show significant association. From 
these findings, we conclude that tumour size is the strongest factor associated with the 
triple negative breast cancer. Besides that, lymph node involvement is also associated 
with triple negative breast cancer. However, lymph vascular invasion is not associated 
with triple negative vascular breast cancer. 
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1. INTRODUCTION. 
The most common tumors in men are prostate, lung, and colorectal cancers. In 
women, cancers of the breast, lung, and colon and rectum are the most frequent. Cancers 
of the lung, female breast, prostate, and colon/rectum constitute more than 50% of cancer 
diagnoses and cancer deaths in the U.S. population. Breast carcinoma is the most 
common malignancy in women worldwide with more than one million cases and nearly 
600 000 death annually (WHO, 2003).  
 
 
 
 
Figure 1: Estimated cancer incidence by site and sex (2003). 
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The age-adjusted death rates over 50 years of the twentieth century are 
significantly increased in both men and women. However, since 1995 the cancer 
incidence rate in men has stabilized and since 1990 the cancer death rate in men has 
decreased to 18.4%. In women the cancer incidence rate stabilized in 1995 and the cancer 
death rate has decreased to 10.4% since 1991. Nearly 40% cancer death rates are 
decreases are due to reduction in lung cancer deaths in men and breast cancer deaths in 
women.  
 
Reviewed data from Second Report of National Cancer Registry: In year 2003, 
cancer incidences in Malaysia showed there were 3738 female breast cancer cases 
reported, which accounted for 31.0 % of total newly diagnosed cancer in female. Breast 
cancer was the commonest cancer in all ethnic groups and all age groups in females from 
the age of 15 years. The overall age-standardized incidence (ASR) was 46.2 per 100,000 
populations. The age pattern in 2003 showed a peak age specific incidence rate at the 50-
59 age groups in Malays, Chinese, and Indians, and the rates then declined in the older 
age groups. Of the cases diagnosed in 2003, 64.1 % were women in between 40 and 60 
years of age. Chinese had the highest incidence with an ASR of 59.7 per 100,000 
population followed by Indian women with an ASR of 55.8 per 100,000 population and 
Malay women with an ASR of 33.9 per 100,000 population.   
 
According to Kelantan Cancer Registry Report 1999-2003, the commonest cancer 
among females was breast carcinoma with 370 cases or 19.6% out of 1887 cancer cased 
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among the women. The youngest age with breast cancer in the registry was 19 years.  The 
peak age group was between 50-54 years.  
 
Breast cancer is a heterogeneous disease leading clinicians to discover better 
prognostic parameters, and optimize the treatment options (Fernandopulle et al., 2006). 
Pathological prognostic factors are used in clinical practice for a variety of reasons, for 
example, the identification of patients who would benefit from neoadjuvant treatment 
(predominantly patients with grade 3 tumors); those in whom conservation surgery is 
inadvisable (patients with definite vascular channel invasion); and those who may benefit 
from specific treatment modalities (for example: tamoxifen, herceptin) (Denley et al., 
2001). 
 
Early detection of breast cancer and the use of aggressive multimodal treatment 
have successfully resulted in a decrease in the mortality due to the disease. Prognostic 
and predictive factors have been widely used in treatment decisions. These factors 
include: the extent of axillaries lymph node involvement, histological grade, age of the 
patient, status of hormone receptors (HRs) and human epidermal growth factor receptor 2 
(HER2), and involvement of lymphatic or micro vascular spaces. Recent studies suggest 
that breast cancer is a heterogeneous disease and patients with the same diagnostic and 
clinical prognostic profile can have markedly different clinical outcomes. Therefore, 
further understanding of the biology of the disease is needed to improve treatment 
outcome and reduce mortality (Jiyoung Rhee et al., 2008), (Quenel et al., 1995), (Osin 
and Lakhani, 1999). 
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Although one study showed that similar risk factors identified in Western 
populations were responsible for the occurrence of breast cancer in Kelantan (Norsa'adah 
et al., 2005), a few studies had shown that breast cancer behaved differently in different 
population and the trends of this malignancy differed with race and ethnicity (Ghafoor et 
al., 2003), (Shavers and Brown, 2002). Since this malignancy is the most common cancer 
in women in our population, it is essential to have more data regarding the behavior of 
breast cancer in our population.        
 
Triple negative breast cancer is characterized by lack of expression of estrogen 
receptor (ER), progesterone receptor (PR) and HER2/neu. It is noted to be a 
clinicopathologic entity with aggressive behavior and poorer prognosis. Standard therapy 
is associated with high relapse rates and the most appropriate treatment is as yet unknown 
(Cleator et al., 2007).  
 
The objective of this study is to determine the incidence and associations with 
pathologic and non pathologic parameters of triple negative breast cancer patients in 
HUSM. 
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2. LITERATURE REVIEW. 
2.1 General. 
Globally, carcinoma of the breast is the most common malignancy and the leading 
cause of cancer death in women (Parkin et al., 2000).  In 2001, almost 240,000 women 
were diagnosed with breast cancer, and over 40,000 died of the disease. As the 
demographic bulge of the "baby boomers" continues to grow older, the absolute number 
of women with breast cancer is expected to increase by about a third over the next 20 
years, just because of the effect of the aging of the population. It is both ironic and tragic 
that a neoplasm arising in an exposed organ, readily accessible to self-examination and 
clinical diagnosis, continues to exact such a heavy toll.  
 
Breast cancer is characterized by its molecular and clinical heterogeneity. Studies 
using cDNA microarrays and immunohistochemical (IHC) markers (Carey et al., 2006; 
Sorlie et al., 2001) have classified breast cancers into five distinct subtypes: luminal A 
(oestrogen receptor (ER) positive and/or progesterone receptor (PR) positive, human 
epidermal growth factor receptor 2 (Her2) negative), luminal B (ER positive and/or PR 
positive, Her2 positive), Her2 over expressing (ER negative, PR negative, Her2 positive), 
basal-like (ER negative, PR negative, Her2 negative, cytokeratin (CK) 5/6 positive and/or 
epidermal growth factor receptor (EGFR) positive) and normal breast-like tumours. 
Approximately 70% of triple negative breast cancers (ER negative, PR negative, Her2 
negative) express basal markers resulting in the triple-negative subtype commonly being 
used as a surrogate marker for the basal-like subtype . 
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Luminal tumours have been associated with the most favourable prognoses, while 
Her2-overexpressing and basal-like tumours, or their surrogate triple negative tumours, 
have been associated with the worst prognoses (Rakha et al., 2006). For triple-negative 
tumours, the peak risk of recurrence occurs within three years of diagnosis, and mortality 
rates are increased for five years after diagnosis (Dent et al., 2007). The subtype accounts 
for approximately 15% of invasive breast cancers (Bauer et al., 2007) and is commonly 
associated with African American race (Lund et al., 2009), younger age at diagnosis, 
more advanced stage (Bauer et al., 2007), higher grade, high mitotic indices (Carey et al., 
2006), family history of breast cancer (Marilyn et al., 2009) and BRCA1 mutations 
(Sorlie et al., 2006). Although many studies have examined associations between 
common breast cancer risk factors such as race and hormone receptor, few studies have 
explored the relationship between common breast cancer risk factors and the molecular 
subtypes of breast cancer (Marilyn et al., 2009).   
 
Previous studies in Western countries show that triple negative breast cancer has 
aggressive clinical and pathologic features, including onset at a young age, advanced 
stage at diagnosis, high histologic and nuclear grade, high mitotic index, higher 
frequency of unfavourable histologies, and more distant recurrence (Bauer et al., 2007; 
Dent et al., 2007). In addition, evidence indicates that the prevalence and clinical 
outcome of triple negative breast cancer differs among races (Carey et al., 2006). Bauer 
et al. have reported that triple negative breast cancer is more prevalent among non-
Hispanic black compared with other ethnic group, who, when affected with this subtype 
had the worst survival (Bauer et al., 2007). Carey et al. also reported that basal-like 
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breast tumours occurred at a higher prevalence among African-American women 
compared with other racial group (Carey et al., 2006). However, there are limited studies 
of the prevalence, characteristics, and prognosis of triple negative breast cancer in Asian 
populations.  
 
A recent study of Korean patients indicated that the basal-like subtype, which is 
positive for one or more of the basal markers and negative for hormone receptors and 
Her2/neu, was not associated with a poor prognosis. This study also showed that the 
survival rate associated with the basal-like subtype does not differ from that of other 
subtypes, with the exception of the Her2/neu over expressing subtype, which has the 
worst survival rate (Kim et al., 2006). In contrast, a recent study of breast cancer patients 
receiving neoadjuvant chemotherapy showed that triple negative breast cancer was 
associated with shorter survival than other subtypes, even though it was associated with a 
higher response rate (Keam et al., 2007).  
 
International comparisons involving developing countries are few in number. 
Where done, survival differences have been largely attributed to differences in patient's 
age, stage of disease at diagnosis, and the presence of metastasis. Socioeconomic factors, 
differential access to health care, insurance status, co morbidities and tolerance to 
prescribed treatment have also been suggested to determine survival (Alrieza Sadjadi et 
al., 2009). Immigration status and ethnicity may also play a role.  
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A study of breast cancer among ethnic Chinese women reported that those born in 
East Asia had lower survival than those born in the US (Alireza Sadjadi et al., 2009). A 
recent study in British Columbia (BC) compared survival for three cancer sites in 
Chinese, South Asians and the predominantly Caucasian general population and found 
that Chinese women had the highest survival rates for both breast and cervical cancer, 
whereas South Asian women had the highest rate for colorectal cancer and the lowest rate 
for cervical cancer (Alireza Sadjadi et al., 2009).  Patterns in cancer incidence can 
provide important insight into the impact of lifestyle upon cancer development whereas 
patterns in survival can provide information about the burden and severity of cancer.  
 
While the risk of breast cancer in Asian countries is lower than in the West, 
increasing numbers of women are being diagnosed with this disease in parts of Asia, 
including Singapore and Japan. In Singapore, breast cancer is the most common female 
malignancy, accounting for 28% of all malignancies in women. The age standardized rate 
is 54.9 per 100 000 per year (Seow A et al., 2004). There is a large variation in the rates 
of breast cancer among countries (Western countries versus Eastern countries, especially 
Japan), over time within countries, and large increase in the incidence of breast cancer 
among populations migrating from nations with low incidence to those with high 
incidence. These observations indicate the existence of both genetic and environmental  
factors associated with an increased risk of breast cancer development (Beckmann et al., 
1997).   
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2.2 Female breast. 
The class Mammalian is remarkable for the evolution of modified skin 
appendages that provide complete nourishment and immunologic protection for the 
young. In humans, paired mammary glands rest on the pectoralis muscle on the upper 
chest wall.  
 
The breast is composed of specialized epithelium and stroma that give rise to both 
benign and malignant lesions specific to the organ. Six to ten major ductal systems 
originate at the nipple. The keratinizing squamous epithelium of the overlying skin 
continues into the ducts and then abruptly changes to a double-layered cuboidal 
epithelium. A small keratin plug is often found at the duct orifice. The surrounding 
areolar skin is pigmented and supported by smooth muscle. Successive branching of the 
large ducts eventually leads to the terminal duct lobular unit (TDLU). 
 
 In the adult woman, the terminal duct branches into a grapelike cluster of small 
acini to form a lobule. Each ductal system typically occupies over a quarter of the breast, 
and the systems extensively overlap each other. In some women, ducts extend into the 
subcutaneous tissue of the chest wall and into the axilla. 
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2.3 Risk factors. 
The major risk factors for the development of breast cancer are hormonal and 
genetic (family history). Breast carcinomas can, therefore, be divided into sporadic cases, 
possibly related to hormonal exposure, and hereditary cases, associated with family 
history or germ-line mutations. Hereditary carcinoma has received intense scrutiny in the 
hopes that the specific genetic mutations can be identified and that these alterations will 
illuminate the causes of all breast cancer.  
 
The structure and function of the normal breast require complex interactions 
between luminal cells, myoepithelial cells, and stromal cells. The same functions that 
allow for normal formation of new ductal branch points and lobules during puberty and 
pregnancy abrogation of the basement membrane, increased proliferation, escape from 
growth inhibition, angiogenesis, and invasion of stroma can be co-opted during 
carcinogenesis by abnormal epithelial cells, stromal cells, or both (Wiseman et al., 2002). 
While the changes described above are accumulating in the luminal cells (or, less 
commonly, myoepithelial cells), parallel changes also occur due to mutation or epigenetic 
changes (e.g., DNA methylation) or via abnormal signaling pathways in these other cell 
types, resulting in the loss of normal cellular interactions and tissue structure. Loss of 
these normal functions also occurs with age, and this loss might contribute to the 
increased risk of breast cancer in older women. 
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The most established risk factors for breast cancer like early menarche, late age at 
first childbirth and menopause, history of benign breast disease, exposure to ionizing 
radiation are generally associated with only weak or moderate elevations in risk. 
Markedly increased risk occurs in patients with a family history of breast cancer, 
especially at a young age or with various affected family members, or with bilateral 
disease (Beckmann et al., 1997). Other known risk factors include race, length of the life 
time exposure to oestrogen, carcinoma of the contra lateral breast or endometrial, high fat 
diet, cigarette smoking, less exercise, exposure to environmental  toxin such as 
organochlorine pesticides and breast feeding which reduce risk of breast cancer (Cotran 
et al., 2009). However, two-thirds of women developing breast cancer have none of these 
factors (Beckmann et al., 1997).  
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2.4 Classification of Breast Carcinoma. 
 
Benign lesions of the breast can be divided into non-proliferative and proliferative 
lesions. Non-proliferative lesions include cysts, apocrine metaplasia, duct ectasia, and 
mild hyperplasia of the simple or usual type. Proliferative lesions are subdivided into 
those without atypia and those with atypia. Proliferative lesions without atypia 
encompass moderate or florid hyperplasia which have more than four layers of 
epithelium but are cytologically benign. Intraductal papillomas and sclerosing adenosis 
are also grouped into this category. Atypical hyperplasia is a hyperplastic lesion with 
some but not all characteristics of the in situ carcinoma. Atypical hyperplasias are 
subdivided into the lobular and ductal types; the anatomical origin of these lesions is 
similar to that of in situ carcinoma (Beckmann et al., 1997). 
 
Carcinomas are divided into in situ carcinomas and invasive carcinomas. 
Carcinoma in situ refers to a neoplastic population of cells limited to ducts and lobules by 
the basement membrane. In some cases, the cells can extend to the overlying skin without 
crossing the basement membrane and appear clinically as Paget disease. However, 
carcinoma in situ does not invade into lymphatics and blood vessels and cannot 
metastasize. Invasive carcinoma (synonymous with "infiltrating" carcinoma) has invaded 
beyond the basement membrane into the stroma. Here, the cells might also invade into 
the vasculature and thereby reach regional lymph nodes and distant sites. Even the 
smallest invasive breast carcinomas have some capacity to metastasize. 
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Carcinoma in situ was originally classified as ductal or lobular on the basis of the 
resemblance of the involved spaces to ducts and lobules. Invasive ductal and lobular 
carcinomas were named by their association with the characteristic in situ component. 
Although these descriptive terms are still used, all carcinomas are thought to arise from 
the terminal duct lobular unit, and the terms "ductal" and "lobular" do not imply a site or 
cell type of origin.  
 
2.4.1 Carcinoma in Situ. 
Proliferations of the glandular epithelium combined with cellular features of 
malignancy but without infiltration are called carcinoma in situ, distinguished by 
microscopy as the ductal (DCIS) or the lobular (LCIS) form. Both lesions arise in the 
terminal duct lobular unit, and in both; the cells of origin are unknown. 
 
 
 
2.4.1.1 Ductal Carcinoma in Situ (DCIS). 
 
DCIS consists of a malignant population of cells limited to ducts and lobules by 
the basement membrane. The myoepithelial cells are preserved, although they may be 
diminished in number. DCIS is a clonal proliferation and usually involves only a single 
ductal system. However, the cells can spread throughout ducts and lobules and produce 
extensive lesions involving an entire sector of a breast. When DCIS involves lobules, the 
acini are often distorted and unfolded and take on the appearance of small ducts. 
 
With increasing screening activities by mammography the number of these 
preinvasive entities in breast biopsies has considerably increased as microcalcifications 
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detected on X-ray are classical features of the common comedo type of DCIS. Various 
subtypes of DCIS have been described: comedo, cribriform, micropapillary, papillary, 
solid, clinging, signet-ring cell, and cystic hypersecretory. As the major issue in the 
management of DCIS is the risk of progression to invasive carcinoma, several 
classification systems have been suggested according to cellular differentiation, 
cytonuclear malignancy grade, and degree of necrosis. Multicentricity of DCIS has been 
described in a high proportion of histological specimens, but in nearly all cases 
systematic pathological investigations reveal a continuum of DCIS growth in a glandular 
segment. True multicentricity seems therefore to be a rare event (Beckmann et al., 1997). 
 
2.4.1.2 Lobular Carcinoma in Situ (LCIS). 
 
LCIS is always an incidental finding in a biopsy performed for another reason, as 
LCIS is not associated with calcifications or a stromal reaction that would form a density. 
Therefore, it remains infrequent (1% to 6% of all carcinomas) with or without 
mammographic screening. LCIS is bilateral in 20% to 40% of women when both breasts 
are biopsied, compared to 10% to 20% of cases of DCIS. LCIS is more common in young 
women, 80% to 90% of cases occurring prior to menopause. 
 
Because LCIS is frequently multicentric and bilateral and subsequent carcinomas 
occur at equal frequency in both breasts, it has been suggested that LCIS is not a true 
neoplasm but rather is a marker of breast cancer risk. However, the cells of LCIS and 
invasive lobular carcinoma are identical in appearance, and both lack expression of e-
cadherin, the transmembrane protein that is responsible for epithelial cell adhesion. The 
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loss of expression correlates with the histologic appearance of lobular carcinomas as 
single detached cells.  
 
Recent molecular studies, however, indicate that at various genetic loci DCIS and 
LCIS are indistinguishable. This is of particular interest as LCIS does seem to be equally 
liable to go on to invasive ductal and lobular carcinoma (Beckmann et al., 1997). 
 
2.4.2 Invasive (Infiltrating) Carcinoma. 
 
Anatomical histopathology describes the type, grade, and growth parameters of 
each individual breast carcinoma. Concerning the histological type the basic 
classification is made according to the supposed origin within the glandule: ductal or 
lobular type. It has subsequently been shown that this classification is based on a false 
premise, and that the only carcinomas which truly arise within the ducts are the papillary 
carcinomas, the others arising in the functional units of the breast called the lobules. The 
majority of invasive carcinomas are referred to as ductal (85–95%). Within this group 
there are some tumours with characteristic features and an individual name. These 
encompass about 15–20% of all breast cancers, for example, tubular, medullary, 
mucinous, papillary, adenoid cystic, metaplastic, apocrine, squamous, secretory, lipid-
rich, and cystic hypersecretory. 
 
The remaining ductal carcinomas (65–80%) are classified as ‘not otherwise 
specified’ (NOS) or more recently as ‘no special type’ (NST). The abundance of the 
infiltrating lobular carcinoma varies from 3% to 14%. In addition to the classical ‘Indian 
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file’ linear growth pattern, some structural variants are recognized as lobular carcinomas: 
tubular, solid, trabecular and alveolar forms. One-third of all lobular types are mixtures of 
the classical and the variant types. Grade is a semi quantitative description of the nuclear 
and/or architectural dedifferentiation of the tumours. It is of interest that breast 
carcinomas arising in BRCA1 carriers have high-grade tumours with a very high mitotic 
rate but historically are recorded as having a good prognosis. This anomaly requires 
further investigation (Rosen, 2006). 
 
Additional parameters such as lymph or blood vessel invasion, perineural 
invasion, angiogenic capacity, and mode of growth at the tumour front have all been 
reported as important prognostic factors, but there is currently no consensus on their 
application in general practice (Beckmann et al., 1997). 
 
2.4.2.1 Invasive Ductal Carcinoma, No Special Type (NST). 
Invasive ductal carcinomas of no special type include the majority of carcinomas 
(70% to 80%). On gross examination, most carcinomas are firm to hard and have an 
irregular border. Less frequently, carcinomas have a well-circumscribed border and may 
be soft to firm in consistency. These carcinomas display a wide spectrum of appearances. 
Most carcinomas induce a marked increase in dense, fibrous desmoplastic stroma 
replacing fat, giving the tumour a hard consistency on palpation, resulting in a 
mammographic density (scirrhous carcinoma) (Cotran et al., 2009) . 
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The microscopic appearance of invasive ductal carcinoma is highly heterogenous 
with regards to growth pattern, cytologic features, stromal desmoplasia, extent of the 
associated DCIS and contour. Variability in histologic features may even be seen within a 
single case. The tumour cells may be arranged as glandular structures, as nest, cords, or 
trabeculae of various sizes, or as solid sheet. Cytologically, the tumour cells range from 
those that show little deviation from normal breast epithelial cells to those exhibiting 
marked cellular pleomorphism and nuclear atypia (Connolly et al., 2006).       
 
 
2.4.2.2 Invasive Lobular Carcinoma.  
 
Invasive lobular carcinomas usually present like carcinomas of NST as a palpable 
mass or mammographic density. However, about one-fourth of cases has a diffuse pattern 
of invasion without prominent desmoplasia and might produce only a vaguely thickened 
area of the breast or subtle architectural changes on mammography. Metastases can also 
be difficult to detect clinically and radiologically owing to this type of invasion (Cotran et 
al., 2009). 
 
Grossly, most tumours are firm to hard with an irregular margin. Occasionally, 
the tissue may feel diffusely thickened and a discrete tumour mass cannot be defined. The 
histological hallmark of lobular carcinomas is the pattern of single infiltrating tumour 
cells, often only one cell in width (in the form of a single file) or in loose clusters or 
sheets. The desmoplastic response may be minimal or absent. The cells have the same 
cytologic features as LCIS and lack cohesion, without formation of tubules or papillae. 
Signet-ring cells are common. Tumour cells are frequently arranged in concentric rings 
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surrounding normal ducts. Several variants, including tumours with large nests of cells 
and a high degree of pleomorphism, have also been described (Cotran et al., 2009). 
 
 
2.4.2.3 Medullary Carcinoma. 
 
Medullary carcinoma presents as a well-circumscribed mass and may be mistaken 
clinically and radiologically for a fibroadenoma. There is sometimes a history of rapid 
and almost explosive growth. 
 
These tumours do not have the striking desmoplasia of the usual carcinoma and 
therefore are distinctly more yielding on external palpation and on cut section. The 
tumour has a soft, fleshy consistency (medulla is Latin for "marrow") and is well 
circumscribed. The carcinoma is characterized by (1) solid, syncytium-like sheets 
(occupying more than 75% of the tumour) of large cells with vesicular, pleomorphic 
nuclei, containing prominent nucleoli and frequent mitoses; (2) a moderate to marked 
lymphoplasmacytic infiltrate surrounding and within the tumour; (3) grade 2 or 3 nuclei, 
(4) absence of glandular differentiation and (5) a pushing (non infiltrative) border. All 
medullary carcinomas are poorly differentiated. DCIS is minimal or absent (Connolly et 
al., 2006). 
 
 
2.4.2.4 Mucinous (Colloid) Carcinoma. 
 
This unusual type (1% to 6% of all breast carcinomas) also commonly presents as 
a circumscribed mass. It tends to occur in older women and may grow slowly during the 
course of many years. The tumour is extremely soft and has the consistency and 
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appearance of pale gray-blue gelatin. The tumour cells are seen as clusters and small 
islands of cells within large lakes of mucin that push into the adjacent stroma (Cotran et 
al., 2009).  
 
Mucinous carcinoma is characterized by the accumulation of abundant 
extracellular mucin around invasive tumour cell. The relative proportion of secretion and 
neoplastic epithelium vary from one case to the next, but the distribution in any one 
tumour is fairly constant. The proportion of extracellular mucin in the tumour classified 
as pure carcinomas varied from slightly less than 40% to 99.8% (Rosen, 2006).      
 
2.4.2.5 Tubular Carcinoma. 
Tubular carcinomas accounts for only 2% of all breast carcinomas before 
mammographic screening but have increased in frequency representing up to 10% of 
carcinomas less than 1 cm in diameter. Tubular carcinomas are typically detected as 
irregular mammographic densities. Women usually present in their late forties. Tumours 
are multifocal within one breast in 10% to 56% of cases and bilateral in 9% to 38%. 
These tumours consist exclusively of well-formed tubules and are sometimes mistaken 
for benign sclerosing lesions. However, a myoepithelial cell layer is absent, and tumour 
cells are in direct contact with stroma. Cribriform spaces may also be present. Apocrine 
snouts are typical, and calcifications may be present within the lumens. LCIS is 
frequently present, but this association has not been explained (Rosen, 2006). 
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More than 95% of all tubular carcinomas are diploid and express hormone receptors. By 
definition, all are well differentiated. Axillaries metastases occur in fewer than 10% of 
cases unless multiple foci of invasion are present. This subtype is important to recognize 
because of its excellent prognosis. 
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2.5 Mechanisms of Carcinogenesis. 
 
Carcinogenesis is a multistep process involving alterations in at least two distinct 
classes of genes. Protooncogenes are activated qualitatively or quantitatively in certain 
tumours, and they appear to act as positive proliferative signals for neoplastic growth. In 
contrast, tumour suppressor genes are normal genes that must be inactivated or lost for 
tumour development. When active, tumour suppressor genes control neoplastic growth in 
a negative manner (Barrett and Wiseman, 1987).  
 
Genes that promote autonomous cell growth in cancer cells are called oncogenes, 
and their normal cellular counterparts are called protooncogenes. Protooncogenes are 
physiologic regulators of cell proliferation and differentiation; oncogenes are 
characterized by the ability to promote cell growth in the absence of normal mitogenic 
signals. Their products, called oncoproteins, resemble the normal products of 
protooncogenes with the exception that oncoproteins are devoid of important regulatory 
elements. Their production in the transformed cells becomes constitutive, that is, not 
dependent on growth factors or other external signals cell proliferation can be readily 
resolved into the following steps: 
i. The binding of a growth factor to its specific receptor generally located on the cell 
membrane. 
ii. Transient and limited activation of the growth factor receptor, which, in turn, 
activates several signal-transducing proteins on the inner leaflet of the plasma 
membrane. 
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iii. Transmission of the transduced signal across the cytosol to the nucleus via second 
messengers or by signal transduction molecules that directly activate 
transcription. 
iv. Induction and activation of nuclear regulatory factors that initiate DNA 
transcription. 
v. Entry and progression of the cell into the cell cycle, ultimately resulting in cell 
division. 
 
With this background, we can readily identify the strategies used by cancer cells to 
acquire self-sufficiency in growth signals. They can be grouped on the basis of their role 
in growth factor-mediated signal transduction cascades and cell-cycle regulation. 
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Figure 2.1: Flow chart depicting a simplified scheme of the molecular basis of cancer 
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Breast cancer emerges by a multistep process which can be broadly equated to 
transformation of normal cells via the steps of hyperplasia, premalignant change and in 
situ carcinoma. The elucidation of molecular interdependencies, which lead to 
development of primary breast cancer, its progression, and its formation of metastases, is 
the main focus for new strategies targeted at prevention and treatment.  
 
Cytogenetic and molecular genetic analysis of breast cancer samples demonstrates 
that tumour development involves the accumulation of various genetic alterations 
including amplification of oncogenes and mutation or loss of tumour suppressor genes. 
Amplification of certain oncogenes with concomitant over expression of the oncoprotein 
seems to be specific for certain histological types. Loss of normal tumour suppressor 
protein function can occur through sequential gene mutation events (somatic alteration) 
or through a single mutational event of a remaining normal copy, when a germline 
mutation is present.  
 
The second event is usually chromosome loss, mitotic recombination, or partial 
chromosome deletion. Chromosome loci 16q and 17p harbour tumour suppressor genes, 
which seem to be pathognomonic for the development or progression of a specific 
histological subtype. There are an overwhelming number of abnormalities that have been 
identified at the molecular level which fit the model of multistep carcinogenesis of breast 
cancer. When the functions of all of these genes are known and how they participate in 
malignant progression, we will have the tools for a more rational approach to diagnosis, 
prevention and treatment (Beckmann et al., 1997). 
